Pharmacotherapy and targeted interventions are mainstays in the management of various pelvic floor disorders, including overactive bladder, urgency urinary incontinence, and neurogenic bladder. Match each pharmacological agent or intervention with its most critical clinical contraindication or adverse effect profile.
- MirabegronContraindicated in patients with severe, uncontrolled hypertension
- OxybutyninContraindicated in narrow-angle glaucoma; use with extreme caution in dementia
- BethanecholContraindicated in active asthma; can precipitate systemic bradycardia
- Intradetrusor OnabotulinumtoxinACarries a significant risk of postoperative incomplete bladder emptying
Cevap
Mirabegron matches with severe hypertension contraindication; Oxybutynin matches with narrow-angle glaucoma and dementia; Bethanechol matches with active asthma and bradycardia; Intradetrusor OnabotulinumtoxinA matches with the risk of postoperative incomplete bladder emptying.
Each agent targets a specific aspect of bladder neurophysiology. Beta-3 agonists (mirabegron) cause sympathetic activation; antimuscarinics (oxybutynin) block parasympathetic pathways; cholinergic agonists (bethanechol) stimulate parasympathetic pathways; and botulinum toxin directly paralyzes the detrusor muscle. The adverse effect profile of each intervention is a direct result of these respective mechanisms.
Adım Adım Çözüm
Anahtar Kavram
Pharmacological management of urinary incontinence requires careful patient selection based on medication mechanisms and their predictable systemic side effect profiles (anticholinergic effects, adrenergic stimulation, or targeted muscle paralysis).